Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Amendment to Employment Agreement with Chief Executive Officer
As previously disclosed in its Current Report on Form 8-K filed with the
Securities and Exchange Commission (the "SEC") on May 12, 2022, on May 10, 2022,
UpHealth, Inc. (the "Company") entered into an employment agreement (the
"Employment Agreement") with Samuel J. Meckey for Mr. Meckey to be employed as
the Chief Executive Officer of the Company. Capitalized terms used and not
otherwise defined herein shall have the meanings set forth in the Employment
Agreement.
On January 9, 2023, the Company's Board of Directors (the "Board") approved an
Amendment to the Employment Agreement between Mr. Meckey and the Company,
effective as of January 10, 2023 (the "Amendment"), to amend certain of the
compensation terms of Mr. Meckey's employment as Chief Executive Officer of the
Company. The Amendment amends the terms of the Employment Agreement as follows.
The Employment Agreement provided that the Company would grant restricted stock
units ("RSUs") under the Company's 2021 Equity Incentive Plan to Mr. Meckey in
the amount of 4,300,000 (pre-split basis) or 430,000 (post-split basis), with
certain of the RSUs vesting subject to Mr. Meckey's continued provision of
services to the Company as further detailed below (the "Time-Based RSUs"), and
certain of the RSUs being subject to vesting based upon performance. None of the
RSUs to be granted pursuant to the terms of the Employment Agreement had been
granted prior to January 9, 2023. Pursuant to the terms of the Amendment, all of
the 430,000 RSUs to be granted will be Time-Based RSUs, and subject to
Mr. Meckey's continued provision of services to the Company through the
applicable vesting dates, these Time-Based RSUs are eligible to vest in
accordance with the following schedule, as described in the applicable
restricted stock unit agreement: 25% will vest on June 1, 2023 (the "Cliff
Date") and the remaining 75% will vest in equal quarterly installments on each
subsequent August 1st, November 1st, February 1st and June 1st over the three
years following the Cliff Date, such that these Time-Based RSUs will be 100%
vested on the third anniversary of the Cliff Date and in each case subject to
Mr. Meckey's continued services with the Company through each such applicable
vesting date.
In addition, the Employment Agreement provided that Mr. Meckey was supposed to
receive as additional consideration for his services as Chief Executive Officer,
payment of $940,568 on January 1, 2023, subject to applicable withholding.
Pursuant to the terms of the Amendment, this payment is being restructured to be
made with one payment of $500,000 on January 13, 2023 and a second payment of
$458,794.24 on May 31, 2023, with each subject to applicable withholding and
provided that Mr. Meckey remains employed with the Company through each
applicable payment date, and subject to the qualified termination severance
benefit provisions in the Employment Agreement.
The Amendment further provides that all other terms and conditions of the
Employment Agreement shall continue in full force and effect.
The foregoing summary of the terms and conditions of the Amendment and the
Employment Agreement is not complete and is qualified in its entirety by
reference to the full text of the Amendment and the Employment Agreement, which
are included as Exhibit 10.1 to this Current Report on Form 8-K and Exhibit 10.1
to the Company's Quarterly Report on Form 10-Q filed with the SEC on August 15,
2022, respectively, and are incorporated herein by reference.
Restricted Stock Unit Award
On January 9, 2023, the Company's Board approved, upon the recommendation of the
Compensation Committee of the Board (the "Compensation Committee"), the grant to
Mr. Meckey of 430,000 RSUs as provided for in the above-discussed Amendment
pursuant to and subject to the terms of the Company's 2021 Equity Incentive
Plan. These RSUs will vest subject to Mr. Meckey's continued provision of
services to the Company through the applicable vesting dates in accordance with
the following schedule, as described in the applicable restricted stock unit
agreement: 25% will vest on the Cliff Date and the remaining 75% will vest in
equal quarterly installments on each subsequent August 1, November 1, February 1
and June 1 over the three years following the Cliff Date, such that the RSUs
will be 100% vested on June 1, 2026, and in each case subject to Mr. Meckey's
continued services with the Company through each such applicable vesting date.
Chief Financial Officer Base Salary Increase
On January 9, 2023, the Board approved, upon the recommendation of the
Compensation Committee, an increase to the base salary payable to Martin Beck,
the Company's Chief Financial Officer, effective as of January 1, 2023. As
previously reported in the Current Report on Form 8-K filed by the Company with
the SEC on October 25, 2021, prior to this increase, Mr. Beck's base salary was
$350,000 per year, and effective as of January 1, 2023, Mr. Beck's base salary
is $400,000 per year.
--------------------------------------------------------------------------------
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Item
10.1 Amendment to Employment Agreement, dated January 12, 2023, by
and between UpHealth, Inc. and Samuel J. Meckey.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses